Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23


Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy.

Enoru JO, Yang B, Krishnamachari S, Villanueva E, DeMaio W, Watanyar A, Chinnasamy R, Arterburn JB, Perez RG.

PLoS One. 2016 Sep 9;11(9):e0162162. doi: 10.1371/journal.pone.0162162. eCollection 2016.


FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.

Vidal-Martínez G, Vargas-Medrano J, Gil-Tommee C, Medina D, Garza NT, Yang B, Segura-Ulate I, Dominguez SJ, Perez RG.

J Biol Chem. 2016 Sep 23;291(39):20811-21. doi: 10.1074/jbc.M116.744029.


The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.

Benskey MJ, Perez RG, Manfredsson FP.

J Neurochem. 2016 May;137(3):331-59. doi: 10.1111/jnc.13570. Epub 2016 Mar 23. Review.


Dynamic structural flexibility of α-synuclein.

Mor DE, Ugras SE, Daniels MJ, Ischiropoulos H.

Neurobiol Dis. 2016 Apr;88:66-74. doi: 10.1016/j.nbd.2015.12.018. Epub 2015 Dec 31. Review.


Ceftriaxone attenuates acute cocaine-evoked dopaminergic neurotransmission in the nucleus accumbens of the rat.

Barr JL, Rasmussen BA, Tallarida CS, Scholl JL, Forster GL, Unterwald EM, Rawls SM.

Br J Pharmacol. 2015 Nov;172(22):5414-24. doi: 10.1111/bph.13330. Epub 2015 Oct 22.


Effect of amyloids on the vesicular machinery: implications for somatic neurotransmission.

Das AK, Pandit R, Maiti S.

Philos Trans R Soc Lond B Biol Sci. 2015 Jul 5;370(1672). pii: 20140187. doi: 10.1098/rstb.2014.0187. Review.


Models of α-synuclein aggregation in Parkinson's disease.

Giráldez-Pérez R, Antolín-Vallespín M, Muñoz M, Sánchez-Capelo A.

Acta Neuropathol Commun. 2014 Dec 13;2:176. doi: 10.1186/s40478-014-0176-9. Review.


Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.

Gombash SE, Manfredsson FP, Kemp CJ, Kuhn NC, Fleming SM, Egan AE, Grant LM, Ciucci MR, MacKeigan JP, Sortwell CE.

PLoS One. 2013 Nov 27;8(11):e81426. doi: 10.1371/journal.pone.0081426. eCollection 2013.


Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.

Farrell KF, Krishnamachari S, Villanueva E, Lou H, Alerte TN, Peet E, Drolet RE, Perez RG.

J Neurochem. 2014 Feb;128(4):536-46. doi: 10.1111/jnc.12481. Epub 2013 Nov 20.


Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?

Kanaan NM, Manfredsson FP.

J Parkinsons Dis. 2012;2(4):249-67. doi: 10.3233/JPD-012138. Review.


The effect of environmental enrichment on substantia nigra gene expression after traumatic brain injury in rats.

Shin SS, Bales JW, Yan HQ, Kline AE, Wagner AK, Lyons-Weiler J, Dixon CE.

J Neurotrauma. 2013 Feb 15;30(4):259-70. doi: 10.1089/neu.2012.2462. Epub 2013 Feb 5.


Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family.

Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL.

J Neurosci. 2011 May 18;31(20):7264-74. doi: 10.1523/JNEUROSCI.6194-10.2011.


Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?

Greggio E, Bisaglia M, Civiero L, Bubacco L.

Mol Neurodegener. 2011 Jan 18;6(1):6. doi: 10.1186/1750-1326-6-6.


α-Synuclein and dopamine at the crossroads of Parkinson's disease.

Venda LL, Cragg SJ, Buchman VL, Wade-Martins R.

Trends Neurosci. 2010 Dec;33(12):559-68. doi: 10.1016/j.tins.2010.09.004. Epub 2010 Oct 18. Review.


Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo.

Lou H, Montoya SE, Alerte TN, Wang J, Wu J, Peng X, Hong CS, Friedrich EE, Mader SA, Pedersen CJ, Marcus BS, McCormack AL, Di Monte DA, Daubner SC, Perez RG.

J Biol Chem. 2010 Jun 4;285(23):17648-61. doi: 10.1074/jbc.M110.100867. Epub 2010 Mar 31.


Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells.

Bisaglia M, Greggio E, Maric D, Miller DW, Cookson MR, Bubacco L.

BMC Neurosci. 2010 Mar 25;11:41. doi: 10.1186/1471-2202-11-41.


Alpha-synuclein disrupted dopamine homeostasis leads to dopaminergic neuron degeneration in Caenorhabditis elegans.

Cao P, Yuan Y, Pehek EA, Moise AR, Huang Y, Palczewski K, Feng Z.

PLoS One. 2010 Feb 19;5(2):e9312. doi: 10.1371/journal.pone.0009312.


DJ-1 deficient mice demonstrate similar vulnerability to pathogenic Ala53Thr human alpha-syn toxicity.

Ramsey CP, Tsika E, Ischiropoulos H, Giasson BI.

Hum Mol Genet. 2010 Apr 15;19(8):1425-37. doi: 10.1093/hmg/ddq017. Epub 2010 Jan 20.


Oxidative status of DJ-1-dependent activation of dopamine synthesis through interaction of tyrosine hydroxylase and 4-dihydroxy-L-phenylalanine (L-DOPA) decarboxylase with DJ-1.

Ishikawa S, Taira T, Niki T, Takahashi-Niki K, Maita C, Maita H, Ariga H, Iguchi-Ariga SM.

J Biol Chem. 2009 Oct 16;284(42):28832-44. doi: 10.1074/jbc.M109.019950. Epub 2009 Aug 24.


14-3-3zeta contributes to tyrosine hydroxylase activity in MN9D cells: localization of dopamine regulatory proteins to mitochondria.

Wang J, Lou H, Pedersen CJ, Smith AD, Perez RG.

J Biol Chem. 2009 May 22;284(21):14011-9. doi: 10.1074/jbc.M901310200. Epub 2009 Mar 16.

Items per page

Supplemental Content

Support Center